Jorge Mestre-Ferrandiz

• Diagnostics and Imaging
• Pricing and Reimbursement
• Health Technology Assessment…
• Precision Medicine
• Value-Based Pricing

The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics

Read more

• Dementia
• Mental Health
• Dementia
• Drug Development/R&D
• Real World Evidence (RWE)

Dementia: The R&D Landscape

Read more

• Health Policy and Regulation
• Multi-Indication Medicines
• NHS
• Pricing and Reimbursement
• UK
• Combination Therapies
• Indication-Based Pricing
• Value-Based Pricing

Multi-indication Pricing: Pros, Cons and Applicability to the UK

Read more

• Cancer
• HTA
• Innovation
• NICE
• Oncology
• Health Technology Assessment…

The Expanding Value Footprint of Oncology Treatments

Read more

• Drug Development/R&D
• Real World Evidence (RWE)

The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness

Read more